Browsing by keyword "apremilast"

Now showing items 1-2 of 2

    • Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy
      Holcomb, Zachary E.; Santillan, Monica Rosales; Morss-Walton, Peyton C.; Salian, Prerna; Her, Min Ji; Giannotti, Nicole M.; Kimball, Alexa B.; Porter, Martina L. (2020-07-01)
      As the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susceptibility of patients on immunomodulatory therapies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. While general guidance has been put forth, data regarding infection rate and outcomes in immunosuppressed patients is still rare.1 Recent articles, including the work by Gisondi, et al, suggest that outcomes of patients on systemic immunomodulatory therapies infected with SARS-CoV-2 are similar to the general population.2 These findings may relate to the aberrant cytokine and inflammatory responses in severe COVID-19, which may be treated or partially blunted by cytokine-targeted therapy.3 Given the substantial outbreak of COVID-19 in our community, we tested whether, in addition to similar outcomes, patients on systemic immunomodulatory therapy had similar infection rates compared to the general population.

    • Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies
      Gladman, Dafna D.; Kavanaugh, Arthur; Gomez-Reino, Juan J.; Wollenhaupt, Jurgen; Cutolo, Maurizio; Schett, Georg; Lespessailles, Eric; Guerette, Benoit; Delev, Nikolay; Teng, Lichen; et al. (2018-06-27)
      Objective: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to disability and affecting quality of life. PALACE 1, 2 and 3 data were pooled to assess the efficacy of apremilast on enthesitis and dactylitis outcomes in patients with these conditions at baseline. Methods: Patients with enthesitis (n=945) or dactylitis (n=633) at baseline were analysed after receiving double-blind treatment with placebo, apremilast 30 mg two times per day or apremilast 20 mg two times per day up to 52 weeks and continuing up to 5 years. Data were analysed through 156 weeks. Enthesitis was evaluated by Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and dactylitis via dactylitis count. Results: At week 24, patients receiving apremilast 30 mg two times per day demonstrated a significantly greater mean change in enthesitis (-1.3 vs -0.9; p < 0.05) and dactylitis (-1.8 vs -1.3; p < 0.01) vs placebo. Patients in the 30 mg dose group showed significantly greater mean (-23.6% vs -7.0%; p < 0.05) and median (-50.0% vs -21.1%; p < 0.05) per cent changes in MASES; mean and median per cent changes in dactylitis count were numerically, but not significantly, different for either apremilast dose in patients with dactylitis. In the patient population remaining on apremilast, observed mean and median improvements in both conditions were sustained through 156 weeks. Conclusion: Apremilast is effective for the treatment of active PsA, including improvements in enthesitis and dactylitis up to 3 years. Trial registration numbers: NCT01172938, NCT01212757 and NCT01212770.